伏立康唑静脉滴注致黄视

Yellow vision produced by intravenous infusion of voriconazole

1例77岁男性患者,因慢性阻塞性肺疾病伴肺部感染给予亚胺培南-西司他丁钠0.5 g入0.9%氯化钠注射液100 ml,3次/d静脉滴注;利奈唑胺0.6 g,2次/d静脉滴注;氨溴索0.045 g入0.9%氯化钠注射液50 ml,2次/d静脉滴注。因曲霉菌感染于第4天加用伏立康唑0.2 g,2次/d静脉滴注。第3次静脉滴注伏立康唑后,患者出现视物黄色,遂将伏立康唑改为0.2g,2次/d口服,其余药物继续应用。口服用药第2天,患者黄视症状明显减轻;第6天,症状完全消失。继续口服伏立康唑9d,其间患者未再出现黄视。

A 77-year-old male patient received an IV infusion of imipenem/cilastatin sodium 0.5 g in 0.9% sodium chloride 100 ml thrice daily,followed by an IV infusion of linezolid 0.6 g twice daily,then an IV infusion of ambroxol 0.045 g in 0.9% sodium chloride 50 ml twice daily for chronic obstructive pulmonary diseases accompanied by pulmonary infections.An IV infusion of voriconazole 0.2 g twice daily was added to his regimen due to Aspergillus infection.After the third intravenous administration of voriconazole,the patient developed yellow vision.Subsequently,his treatment was switched to oral administration of voriconazole 0.2 g twice daily and other drugs were continued.On day 2 of oral administration,his yellow vision was significantly relieved and,on day 6,his symptoms subsided completely.His yellow vision did not recur after further 9 days of oral voriconazole therapy.